I'd like to remind everyone, and any new investors who may be reading and not posting, that Leo has stated many times over the years that CTIX was not looking to partner or sell their drugs until they felt that they have maximized the value of them. I am sure it is highly likely that CTIX could partner or sell just about any of the drugs right now, as-is, but they will not receive as good a price for them as they will with the later stage trial data. Plus as the drugs succeed in later trials risk is reduced, and reduced risk for BP is worth lots of additional money. Leo is a shareholder and Menon is a shareholder; if they are confident that the drugs are working well, and that they have enough funding to continue pursuing trials for the next year, what motivation do they have to diminish value just for the sake of partnership in the short term?

I am fully aware that CTIX does not currently have the funding to get any of the drugs through a phase 3 and to market, but they have sufficient funds for a year to continue trials and increase the value of the drugs for the future partnership/sale. Plus, if the plan doesn't work to get a better deal in the future, and management has been choosing to pass on less than stellar deals, then that tells me the worst case scenario backup plan is that they will partner or sell a drug for less money in order to keep solvent. It would not be ideal to have to do that, but I think that is a worthwhile gamble for the potential of stellar returns upon future trial success.

So that is why I do not put any weight to the continued statements that CTIX can't find a partner, or is somehow screwed and going to go bankrupt. They are choosing to continue down this short term path (which I admit is painful as a shareholder to see paper losses) in order to create a better long term gain for all of us.